• Special Issue Topic
    Immunotherapy in Cancer Patients
    Submission Deadline: September 30, 2020

    Guest Editor

    Prof. Rossana Berardi E-Mail

    Professor in Medical Oncology and Director of the Postgraduate School of Medical Oncology at Università Politecnica Marche; Director of Department of Medical Oncology, Director of “Genetic Cancer” Center and Breast Unit Coordinator at Ospedali Riuniti of Ancona, Italy

    Research Keywords: thoracic cancer; breast cancer; neuroendocrine tumors; innovative therapies; COVID-19 and cancer

    About the Special Issue

    Immunotherapy in the last years improved outcome of cancer patients, inducing durable tumour responses, in particular in patients affected by NSCLC and melanoma. Immune checkpoint inhibitors regulate and stimulate the immune system to recognize and attack tumour cells. It is commonly better tolerated than chemotherapy and targeted therapy with a unique toxicity profile depending on their different of mechanism of activity.
    These toxicities, despite rare, can be sometimes disabling.
    However, some patients do not benefit from immunotherapy. Several original researches investigated the potential predictive role of clinical, pathological, laboratoristic factors to select responder patients.
    Notwithstanding, a validated predictive parameters do not detected.
    Immunotoxicity could involve all organs and systems requiring a specific management including steroids, immunomodulating therapy in multidisciplinary approach. Pathophysiology of immune-toxicity is still unclear. Parameters potentially associated with increased risk of immune-related adverse events are still under investigation.
    This special issue focus on predictive factors of response and toxicity in cancer patients treated with immunotherapy in order to improve the management of those subjects.

    logo.pngWomen for Oncology – Italy supports this special issue.

    Keywords: immunotherapy; immune-related toxicity; multidisciplinary approach

    Call for Papers

    Published Articles

    Open Access
    Letter to the Editor
    Is hyperprogressive disease a specific phenomenom of immunotherapy?
    Hyperprogressive disease (HPD) is a novel pattern of response during immunotherapy treatment. Several retrospective studies have evaluated its prevalence among various cancer types and, in particula...
    Marta Brambilla ... Mario Occhipinti
    Published: December 28, 2020 Explor Target Antitumor Ther. 2020;1:427-433
    DOI: https://doi.org/10.37349/etat.2020.00027
    Times Cited: 0
    Open Access
    An overview of immune checkpoint inhibitors in breast cancer
    Although breast cancer is not traditionally considered an immunogenic type of tumor, the combination of immunotherapy and chemotherapy has recently emerged as a novel treatment option in triple-nega...
    Federica Miglietta ... Nicla La Verde
    Published: December 28, 2020 Explor Target Antitumor Ther. 2020;1:452-472
    DOI: https://doi.org/10.37349/etat.2020.00029
    Times Cited:
    Open Access
    Case Report
    Pseudoprogression in lung cancer: a case report
    Immunotherapy dramatically changed the management of several malignancies including non-small cell lung cancer (NSCLC). Since immune checkpoint inhibitors have a different mechanism of action from c...
    Giulia Meoni ... Angela Stefania Ribecco
    Published: October 30, 2020 Explor Target Antitumor Ther. 2020;1:372-380
    DOI: https://doi.org/10.37349/etat.2020.00022
    Times Cited: 0